Hansa Biopharma AB (publ) (HNSBF)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 844.9 Million SEK | 7.78% |
| 2022 | 783.92 Million SEK | 2651.49% |
| 2021 | 28.49 Million SEK | 4422.38% |
| 2020 | 630 Thousand SEK | -86.95% |
| 2019 | 4.82 Million SEK | 914.08% |
| 2018 | 476 Thousand SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 4000.00 SEK | -91.84% |
| 2015 | 49 Thousand SEK | -46.15% |
| 2014 | 91 Thousand SEK | -30.53% |
| 2013 | 131 Thousand SEK | -22.02% |
| 2012 | 168 Thousand SEK | -17.65% |
| 2011 | 204 Thousand SEK | 0.0% |
| 2010 | - SEK | -100.0% |
| 2009 | 8 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 927.11 Million SEK | 9.73% |
| 2024 Q2 | 956.35 Million SEK | 3.15% |
| 2024 Q3 | 942.95 Million SEK | -1.4% |
| 2023 Q4 | 844.9 Million SEK | -8.41% |
| 2023 FY | 844.9 Million SEK | 7.78% |
| 2023 Q1 | 817.19 Million SEK | 4.24% |
| 2023 Q2 | 858.59 Million SEK | 5.07% |
| 2023 Q3 | 922.51 Million SEK | 7.44% |
| 2022 Q1 | 26.72 Million SEK | -6.21% |
| 2022 Q2 | 24.94 Million SEK | -6.67% |
| 2022 FY | 783.92 Million SEK | 2651.49% |
| 2022 Q3 | 783.93 Million SEK | 3043.28% |
| 2022 Q4 | 783.92 Million SEK | -0.0% |
| 2021 Q2 | 17.64 Million SEK | 2931.79% |
| 2021 Q1 | 582 Thousand SEK | -7.62% |
| 2021 FY | 28.49 Million SEK | 4422.38% |
| 2021 Q3 | 16.39 Million SEK | -7.1% |
| 2021 Q4 | 28.49 Million SEK | 73.81% |
| 2020 Q1 | 4.71 Million SEK | -2.4% |
| 2020 Q4 | 630 Thousand SEK | -56.4% |
| 2020 Q3 | 1.44 Million SEK | -45.45% |
| 2020 Q2 | 2.64 Million SEK | -43.77% |
| 2020 FY | 630 Thousand SEK | -86.95% |
| 2019 Q3 | 6.08 Million SEK | -14.61% |
| 2019 Q1 | 9.28 Million SEK | 1851.26% |
| 2019 Q2 | 7.13 Million SEK | -23.23% |
| 2019 FY | 4.82 Million SEK | 914.08% |
| 2019 Q4 | 4.82 Million SEK | -20.71% |
| 2018 Q4 | 476 Thousand SEK | -59.56% |
| 2018 Q2 | 668 Thousand SEK | 2.45% |
| 2018 Q1 | 652 Thousand SEK | 0.0% |
| 2018 FY | 476 Thousand SEK | 0.0% |
| 2018 Q3 | 1.17 Million SEK | 76.2% |
| 2017 Q3 | 574 Thousand SEK | 1.23% |
| 2017 Q2 | 567 Thousand SEK | 1.43% |
| 2017 Q1 | 559 Thousand SEK | 13875.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q4 | - SEK | -100.0% |
| 2016 Q3 | 547 Thousand SEK | 1925.93% |
| 2016 Q4 | 4000.00 SEK | -99.27% |
| 2016 FY | 4000.00 SEK | -91.84% |
| 2016 Q2 | 27 Thousand SEK | -28.95% |
| 2016 Q1 | 38 Thousand SEK | -22.45% |
| 2015 Q1 | 81 Thousand SEK | -10.99% |
| 2015 Q2 | 69 Thousand SEK | -14.81% |
| 2015 Q4 | 49 Thousand SEK | -18.33% |
| 2015 Q3 | 60 Thousand SEK | -13.04% |
| 2015 FY | 49 Thousand SEK | -46.15% |
| 2014 Q4 | 91 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 FY | 91 Thousand SEK | -30.53% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q4 | 131 Thousand SEK | 0.0% |
| 2013 FY | 131 Thousand SEK | -22.02% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q3 | 131 Thousand SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q4 | 168 Thousand SEK | 0.0% |
| 2012 FY | 168 Thousand SEK | -17.65% |
| 2011 Q4 | 204 Thousand SEK | 0.0% |
| 2011 FY | 204 Thousand SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | -100.0% |
| 2009 FY | 8 Million SEK | 0.0% |
| 2009 Q4 | 8 Million SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -514441.579% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -68682.955% |
| Evofem Biosciences, Inc. | 8000.00 USD | -10561187.5% |
| GB Sciences, Inc. | 322 Thousand USD | -262292.236% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -493331.642% |
| Zenith Capital Corp. | 4456.00 USD | -18960918.851% |
| Agentix Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -38130.905% |
| CSL Limited | 11.23 Billion USD | 92.482% |
| CytoDyn Inc. | 141 Thousand USD | -599121.986% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -4059.625% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -1440681.351% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -564621.884% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -48029.485% |
| SQZ Biotechnologies Company | 20.9 Million USD | -3940.858% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -15328328.882% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Mesoblast Limited | 100.29 Million USD | -742.418% |
| Marizyme, Inc. | 667.12 Thousand USD | -126547.62% |
| Genus plc | 228.2 Million USD | -270.247% |
| Pharming Group N.V. | 166.1 Million USD | -408.656% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -60124.002% |
| IMV Inc. | 27.39 Million USD | -2983.748% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -15470.001% |
| MultiCell Technologies, Inc. | 36.43 USD | -2319250517.623% |
| ONE Bio Corp. | 592.19 Thousand USD | -142572.383% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -1419.282% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -37856.11% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -3339569.552% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -44404.464% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| Enzolytics Inc. | - USD | -Infinity% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -5402.82% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 287.12 Million USD | -194.259% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -668854.569% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -368385.026% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -10123.899% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -152247.32% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -317969.155% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -563168.667% |
| Resverlogix Corp. | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -367743.32% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -79408076.692% |
| LadRx Corporation | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -564621.884% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| International Stem Cell Corporation | 445 Thousand USD | -189765.843% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -1056028.75% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -10704.441% |
| SYBLEU INC | 300 Thousand USD | -281534.333% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -228840.601% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -10266.908% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -184780.306% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -72673.73% |
| PureTech Health plc | 18.25 Million USD | -4529.605% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -563168.667% |
| IXICO plc | 275 Thousand USD | -307137.455% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -7036.608% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -3111.46% |
| CSL Limited | 11.23 Billion USD | 92.482% |
| Cellectis S.A. | 36.21 Million USD | -2233.268% |